These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 22470545)

  • 1. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
    Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
    PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
    Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
    J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
    Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S
    J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
    Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
    Agger EM; Rosenkrands I; Hansen J; Brahimi K; Vandahl BS; Aagaard C; Werninghaus K; Kirschning C; Lang R; Christensen D; Theisen M; Follmann F; Andersen P
    PLoS One; 2008 Sep; 3(9):e3116. PubMed ID: 18776936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
    Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
    Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
    Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
    Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.
    Nordly P; Agger EM; Andersen P; Nielsen HM; Foged C
    Pharm Res; 2011 Mar; 28(3):553-62. PubMed ID: 21042837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
    Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
    Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
    Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple nanoliposomes encapsulating
    Bo R; Sun Y; Zhou S; Ou N; Gu P; Liu Z; Hu Y; Liu J; Wang D
    Int J Nanomedicine; 2017; 12():6289-6301. PubMed ID: 28894367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
    Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
    Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.
    Akache B; Stark FC; Jia Y; Deschatelets L; Dudani R; Harrison BA; Agbayani G; Williams D; Jamshidi MP; Krishnan L; McCluskie MJ
    PLoS One; 2018; 13(12):e0208067. PubMed ID: 30513093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice.
    Kar UK; Jiang J; Champion CI; Salehi S; Srivastava M; Sharma S; Rabizadeh S; Niazi K; Kickhoefer V; Rome LH; Kelly KA
    PLoS One; 2012; 7(7):e38553. PubMed ID: 22808011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.
    Kaur R; Bramwell VW; Kirby DJ; Perrie Y
    J Control Release; 2012 Feb; 158(1):72-7. PubMed ID: 22032883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
    Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
    Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice.
    Gram GJ; Karlsson I; Agger EM; Andersen P; Fomsgaard A
    PLoS One; 2009 Sep; 4(9):e6950. PubMed ID: 19759892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses.
    Rizwan SB; McBurney WT; Young K; Hanley T; Boyd BJ; Rades T; Hook S
    J Control Release; 2013 Jan; 165(1):16-21. PubMed ID: 23142776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.